Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Blaze Bioscience Inc. is currently prosecuting 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed between 2 distinct examiners, providing the company with two different points of contact at the patent office. JONES, DAMERON LEVEST is identified as the busiest examiner, currently handling 1 pending office action. This distribution means that the company's current workload is evenly split, with each of the 2 distinct examiners managing one-half of the pending matters.
The portfolio's technical scope is reflected in the involvement of 2 distinct art units. This indicates that the 2 pending office actions fall under different technical classifications, each subject to its own art unit's standards. For practitioners, this means that the prosecution strategy must be adapted to two different sets of technical benchmarks. The fact that 2 distinct examiners are involved ensures that the company is not overly dependent on the tendencies of a single official.
With 2 pending office actions spread across 2 distinct art units, the company faces a diversified prosecution environment. Because JONES, DAMERON LEVEST handles 1 pending office action, the legal team can focus on the specific requirements of each case independently. This structure allows for a variety of examiner interactions while maintaining a manageable number of active matters. Practitioners should monitor both of the 2 distinct art units for any procedural differences that could affect the company's overall intellectual property goals.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| JONES, DAMERON LEVEST | 1 | 67.7% | +31.3% |
| PETERS, ALEC JON | 1 | 66.7% | +54.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18618998 | CHLOROTOXIN CONJUGATES AND METHODS OF USE THEREOF | JONES, DAMERON LEVEST | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18618998 | CHLOROTOXIN CONJUGATES AND METHODS OF USE THEREOF | JONES, DAMERON LEVEST | — |
| 18037923 | COMPOSITIONS AND METHODS FOR SELECTIVE DEPLETION OF TARGET MOLECULES | PETERS, ALEC JON | — |
| Art Unit | Apps |
|---|---|
| 1618 | 1 |
| 1641 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18618998 | CHLOROTOXIN CONJUGATES AND METHODS OF USE THEREOF | JONES, DAMERON LEVEST | 1618 | §103§112Other | Non-Final OA | — | Pending | Mar 27, 2024 |
| 18037923 | COMPOSITIONS AND METHODS FOR SELECTIVE DEPLETION OF TARGET MOLECULES | PETERS, ALEC JON | 1641 | §102§103§112DP | Non-Final OA | — | Pending | May 19, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial